Smith & Nephew is a global medical technology company founded in 1856 in Hull, England, and now listed on both the London Stock Exchange and the New York Stock Exchange as a constituent of the FTSE 100. The company designs and manufactures products for the repair, regeneration and replacement of soft and hard tissue, serving millions of patients annually across more than 100 countries. Its Brazilian entity, BRA - Smith & Nephew Comercio de Produtos Medicos LTDA, operates as part of this global network.
The business is organised into three global units: Orthopaedics, Sports Medicine + ENT (ear, nose and throat), and Advanced Wound Management. Its product portfolio spans robotics-assisted surgery, bioinductive implants and wound care technologies, with notable products including the CORI Surgical System for robotics-assisted orthopaedic procedures, the REGENETEN Bioinductive Implant for tissue regeneration, and the PICO negative pressure wound therapy device.
With over 18,000 employees worldwide, Smith & Nephew operates at significant scale across clinical and commercial functions. The company's work spans challenging clinical needs - from advanced wound care to complex musculoskeletal procedures - and its technologies have been applied in high-demand recovery contexts, including elite sport.
